A panel of monoclonal antibodies (BA-1, BA-2 and BA-3) were made against the pre-B acute lymphoblastic leukemia (ALL) cell line NALM-6. BA-3 binds to the 100,000 mol. wt common ALL antigen (gp100/CALLA), BA-2 binds to a 24,000 mol. wt (p24) cell surface structure and BA-1 binds to a currently undefined antigen. These antibodies were analysed for their reactivity with 67 human leukemia/lymphoma cell lines. The cell lines studied included T ALL, non-T ALL. surface immunoglobulin+ leukemias/lymphomas, and myeloid/monocytoid leukemias. The results indicate that all three antibodies react primarily (but not exclusively) with malignant cells early in B cell development. This pattern of reactivity was similar to previous results obtained with fresh, non-cultured malignant cells. BA-1, BA-2 and BA-3 are useful tools for analysing the developmental options of normal lymphoid cells and for "cleaning up" leukemia/lymphoma cells in selected cases of autologous bone marrow transplantation.
Bibliographical noteFunding Information:
Supported by grants CA-25097, CA-14413. contract CB-84261 and New Investigator Award CA-28526 (to T.W.LI from the National Cancer Institute, National Institutes of Health, and by a grant from the University of Minnesota Graduate School. Ahhret'iations: ALL. acute lymphoblastic leukemia; Ig, immunoglobulin; TdT, terminal deoxynucleotidyl transferase: CALLA. common ALL antigen; NHL, non-Hodgkin's lymphoma; BL, Burkitt's lymphoma. Correspondence to: Dr. T. LeBien, Box 609 Mayo, Department of Laboratory Medicine and Pathology° University of Minnesota, Minneapolis, MN 55455, U.S.A.
- Monoclonal antibodies
- leukemia/lymphoma cell lines